The current role of secondary cytoreductive surgery for recurrent ovarian cancer

被引:8
作者
de Bree, Eelco [1 ]
Michelakis, Dimosthenis [1 ]
Anagnostopoulou, Elisavet [1 ]
机构
[1] Crete Univ Hosp, Dept Surg Oncol, Med Sch, Iraklion, Greece
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
ovarian cancer recurrence; secondary cytoreductive surgery; patient selection; platinum-sensitive; predictive tools; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; PERITONEAL SURFACE MALIGNANCIES; LEARNING-CURVE; PROGRESSION-FREE; PREDICTION MODELS; AGO SCORE; SURVIVAL; BEVACIZUMAB; MAINTENANCE; MULTICENTER;
D O I
10.3389/fonc.2022.1029976
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian cancer represents worldwide the second most frequent and the most fatal gynecological malignancy, with approximately two thirds of the patients presenting with advanced disease. Cytoreductive surgery, primary or after neoadjuvant chemotherapy, in combination with platinum-based chemotherapy is the standard of care for these patients. Despite the improvement in quality of cytoreductive surgery as well as development of novel drugs and chemotherapy regimens, still most women with ovarian cancer will ultimately develop recurrent disease and die of their disease. In contrast to the management of primary disease, the standard treatment of patients with recurrent ovarian cancer remains a topic of debate. While platinum-based or second line systemic chemotherapy, depending on the time after last platinum treatment, is standard of care, the role of secondary cytoreductive surgery has been a controversial issue for the last decades. Potential outcome benefit must be also weighed against the risk of severe surgical morbidity, impairment of quality of life and costs. In platinum-resistant recurrent disease, i.e., relapse after less than 6 months from the last platinum-based chemotherapy for primary disease, secondary cytoreduction seems generally not to be indicated due to its aggressive biological behavior and the absence of effective systemic treatment. In this comprehensive review, the current role of cytoreductive surgery in platinum-sensitive recurrent ovarian cancer is discussed thoroughly in view of the results of most recent randomized trials and a meta-analysis. There seems to be definitely a role for secondary cytoreductive surgery in selected patients with ovarian cancer recurrence in whom complete resection of macroscopic disease is feasible. However, its role should be continuously reviewed due to the changing systemic treatment of patients with ovarian cancer recurrence over time.
引用
收藏
页数:12
相关论文
共 89 条
[21]   Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer [J].
Coleman, Robert L. ;
Spirtos, Nick M. ;
Enserro, Danielle ;
Herzog, Thomas J. ;
Sabbatini, Paul ;
Armstrong, Deborah K. ;
Kim, Jae-Weon ;
Park, Sang-Yoon ;
Kim, Byoung-Gie ;
Nam, Joo-Hyun ;
Fujiwara, Keiichi ;
Walker, Joan L. ;
Casey, Ann C. ;
Alvarez Secord, Angeles ;
Rubin, Steve ;
Chan, John K. ;
DiSilvestro, Paul ;
Davidson, Susan A. ;
Cohn, David E. ;
Tewari, Krishnansu S. ;
Basen-Engquist, Karen ;
Huang, Helen Q. ;
Brady, Mark F. ;
Mannel, Robert S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (20) :1929-1939
[22]   Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review [J].
Conte, Carmine ;
Fagotti, Anna ;
Avesani, Giacomo ;
Trombadori, Charlotte ;
Federico, Alex ;
D'Indinosante, Marco ;
Giudice, Maria Teresa ;
Pelligra, Silvia ;
Lodoli, Claudio ;
Marchetti, Claudia ;
Ferrandina, Gabriella ;
Scambia, Giovanni ;
Gallotta, Valerio .
ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (06)
[23]   A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer [J].
Cowan, Renee A. ;
Eriksson, Ane Gerda Zahl ;
Jaber, Sara M. ;
Zhou, Qin ;
Iasonos, Alexia ;
Zivanovic, Oliver ;
Leitao, Mario M., Jr. ;
Abu-Rustum, Nadeem R. ;
Chi, Dennis S. ;
Gardner, Ginger J. .
GYNECOLOGIC ONCOLOGY, 2017, 145 (02) :230-235
[24]  
de Bree Eelco, 2007, Recent Results Cancer Res, V169, P39
[25]   An overview and update of hyperthermic intraperitoneal chemotherapy in ovarian cancer [J].
de Bree, Eelco ;
Michelakis, Dimosthenis .
EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (12) :1479-1492
[26]  
de Bree E, 2017, PLEURA PERITONEUM, V2, P47, DOI [10.1515/pp-2017-0010, 10.1515/pap-2017-0010]
[27]   2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) [J].
du Bois, A ;
Quinn, M ;
Thigpen, T ;
Vermorken, J ;
Avall-Lundqvist, E ;
Bookman, M ;
Bowtell, D ;
Brady, M ;
Casado, A ;
Cervantes, A ;
Eisenhauer, E ;
Friedlaender, M ;
Fujiwara, K ;
Grenman, S ;
Guastalla, JP ;
Harper, P ;
Hogberg, T ;
Kaye, S ;
Kitchener, H ;
Kristensen, G ;
Mannel, R ;
Meier, W ;
Miller, B ;
Neijt, JP ;
Oza, A ;
Ozols, R ;
Parmar, M ;
Pecorelli, S ;
Pfisterer, J ;
Poveda, A ;
Provencher, D ;
Pujade-Lauraine, E ;
Randall, M ;
Rochon, J ;
Rustin, G ;
Sagae, S ;
Stehman, F ;
Stuart, G ;
Trimble, E ;
Vasey, P ;
Vergote, I ;
Verheijen, R ;
Wagner, U .
ANNALS OF ONCOLOGY, 2005, 16 :7-12
[28]  
Eisenkop SM, 2000, CANCER, V88, P144, DOI 10.1002/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.3.CO
[29]  
2-O
[30]   Impact of BRCA1/2 Mutations on the Efficacy of Secondary Cytoreductive Surgery [J].
Estati, Felipe Leonardo ;
Pirolli, Rafaela ;
Loiola de Alencar, Viviane Teixeira ;
Goncalves Ribeiro, Adriana Regina ;
Formiga, Maria Nirvana ;
Torrezan, Giovana Tardin ;
Carraro, Dirce Maria ;
Gadelha Guimaraes, Andrea Paiva ;
Baiocchi, Glauco ;
Balieiro Anastacio da Costa, Alexandre Andre .
ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (07) :3637-3645